AURA
Aura Biosciences, Inc.Healthcare·Biotechnology
$7.47
$480M market cap
Revenue
$0.0M
Free Cash Flow
$-50.6M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridg
2-Year Price History
$7.60+1.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -34.6 | -34.9 | -33.7 | -29.9 | -30.0 | -0.1 | 114.7 | 17.0 | 67.5 | -448.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | -27.0 | -27.2 | -25.6 | -20.5 | -20.6 | -0.2 | 144.2 | 17.4 | 60.3 | -176.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$7.47
Market Cap$480M
Enterprise Value$382M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-10.6%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-59.2M
Free Cash Flow$-50.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-312.1%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.2M
Days to Cover8.0
Change (vs Prior)+8.9%
Need at least 2 settlement dates for chart
Employees
Headcount106
Revenue / Employee$0
Gross Profit / Employee$-2,585
Cash Runway
27.2months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
55.9%(+18.4% YoY)
112 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
13.6%(+3.9% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.1%(-0.0% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | $46.3M | $9.59 | +$0 | +$0 | -0.2% | $46.3M |
| Frazier Life Sciences Management, L.P. | $34.1M | $6.26 | +$0 | +$34.1M | +2.3% | $3.89B |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $32.7M | $9.47 | +$0 | +$0 | -0.1% | $64.61B |
| Long Focus Capital Management, LLC | $30.9M | $7.26 | +$0 | +$8.7M | -1.6% | $2.22B |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $29.3M | $6.01 | +$0 | +$11.0M | -9.0% | $3.69B |
| BlackRock, Inc.Passive | $24.0M | $8.49 | +$175K | +$312K | -0.2% | $5.69T |
| Medicxi Ventures Management (Jersey) Ltd | $20.3M | $14.17 | +$0 | +$0 | +8.6% | $982M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $15.0M | $6.69 | +$15.0M | +$15.0M | — | $4.04T |
| Nantahala Capital Management, LLC | $14.2M | $8.39 | +$0 | +$5.7M | -2.3% | $1.60B |
| FRANKLIN RESOURCES INC | $13.9M | $7.71 | −$841K | −$922K | -0.2% | $403.03B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $8.8M | $8.97 | +$371K | +$1.9M | +2.3% | $1.61T |
| MILLENNIUM MANAGEMENT LLC | $7.3M | $6.37 | +$3.2M | +$7.3M | -0.5% | $127.40B |
| STATE STREET CORPPassive | $6.5M | $9.91 | +$255K | +$1.1M | -0.2% | $2.89T |
| LEVIN CAPITAL STRATEGIES, L.P. | $6.3M | $7.84 | −$630K | −$2.8M | +0.4% | $1.31B |
| B Group, Inc. | $4.0M | $7.83 | +$167K | +$836K | -5.3% | $135M |
| ACORN CAPITAL ADVISORS, LLC | $4.0M | $5.86 | +$0 | +$35K | +5.8% | $352M |
| DIMENSIONAL FUND ADVISORS LPPassive | $3.7M | $7.96 | +$269K | +$1.0M | -0.4% | $480.92B |
| BALYASNY ASSET MANAGEMENT LLC | $3.7M | $6.69 | +$3.7M | +$3.7M | -0.4% | $48.01B |
| Regency Capital Management Inc.\DE | $3.6M | $10.28 | −$41K | −$1.5M | +0.1% | $224M |
| NORTHERN TRUST CORPPassive | $2.9M | $9.78 | +$118K | +$375K | -0.2% | $755.34B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
-0.48%
avg per quarter
Holders (ex-self)
-0.36%
excl. this stock
Buyers (this Q)
-0.62%
60 buyers · $0.04B in
Sellers (this Q)
-0.33%
42 sellers · $-0.00B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+19.0%
how holders react when this stock falls
On quiet Qs
+5.5%
−10% to +10% baseline
On rallies (+10%+)
-1.0%
how they react when this stock rises
Holders' portfolio flow this Q
-2.9%
outflows — trims may be forced
Sellers' portfolio flow this Q
+0.3%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-0.2%
Holder mid (any stock)
-3.9%
Holder rally (any stock)
-5.7%
Biggest decreases this quarter
Decheng Capital LLCexited−$2.0MFRANKLIN RESOURCES INC−$841Kα-0.2LEVIN CAPITAL STRATEGIES, L.P.−$630Kα+0.4Resolute Capital Asset Partners LLCexited−$496KJANE STREET GROUP, LLCexited−$258KWalleye Capital LLCexited−$253KPRICE T ROWE ASSOCIATES INC /MD/−$185Kα-0.2HARBOR CAPITAL ADVISORS, INC.exited−$180KOPAL CAPITAL LLCexited−$127KEthic Inc.exited−$96K
New buyers this quarter
Top-5 holders · 50.9%
Matrix Capital Management Company, LP--
Frazier Life Sciences Management, L.P.--
ADAGE CAPITAL PARTNERS GP, L.L.C.--
Long Focus Capital Management, LLC--
SUVRETTA CAPITAL MANAGEMENT, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Matrix Capital Management Company, LP6.9MMedicxi Ventures Management (Jersey) Ltd3.0MEVENTIDE ASSET MANAGEMENT, LLC—CITADEL ADVISORS LLC13KADAGE CAPITAL PARTNERS GP, L.L.C.4.9MFrazier Life Sciences Management, L.P.5.1MLong Focus Capital Management, LLC4.6MSUVRETTA CAPITAL MANAGEMENT, LLC4.4MRock Springs Capital Management LP—Decheng Capital Management III (Cayman), LLC—
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$17.0012760.0%
Last Year (1 analysts)$17.0012760.0%
Current Price$7.47
Analyst Ratings
8
Buy: 8Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$986K
13 txns · 5 insiders · 181,759 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$39.04M
1 txn · 1 insider · 6,922,870 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-07 | SELL | Matrix Capital Management Company, LP | 10 percent owner | 6,922,870 | $5.64 | $39.04M | $0 |
| 2026-04-16 | SELL | Kilroy Conor | officer: See Remarks | 11,738 | $7.02 | $82K | $1.53M |
| 2026-02-17 | SELL | Elazzouzi Amy | officer: Senior Vice President, Finance | 8,549 | $5.06 | $43K | $382K |
| 2026-02-17 | SELL | Hopkins Janet Jill | officer: Chief Medical Officer | 20,401 | $5.06 | $103K | $1.18M |
| 2026-02-17 | SELL | Kilroy Conor | officer: See Remarks | 12,079 | $5.05 | $61K | $845K |
| 2026-02-17 | SELL | Plavsic Mark | officer: Chief Technology Officer | 15,890 | $5.05 | $80K | $916K |
| 2026-02-17 | SELL | de los Pinos Elisabet | director, officer: See Remarks | 47,648 | $5.06 | $241K | $2.07M |
| 2026-01-20 | SELL | Elazzouzi Amy | officer: Senior Vice President, Finance | 1,581 | $4.86 | $8K | $409K |
| 2026-01-20 | SELL | de los Pinos Elisabet | director, officer: See Remarks | 16,928 | $4.86 | $82K | $2.22M |
| 2025-11-17 | SELL | Hopkins Janet Jill | officer: Chief Medical Officer | 17,109 | $5.42 | $93K | $1.37M |
| 2025-10-29 | SELL | Elazzouzi Amy | officer: Senior Vice President, Finance | 896 | $6.35 | $6K | $544K |
| 2025-10-29 | SELL | de los Pinos Elisabet | director, officer: See Remarks | 9,049 | $6.35 | $57K | $3.01M |
| 2025-10-16 | SELL | Plavsic Mark | officer: Chief Technology Officer | 12,169 | $6.35 | $77K | $1.25M |
| 2025-08-18 | SELL | Elazzouzi Amy | officer: Senior Vice President, Finance | 7,722 | $6.70 | $52K | $580K |
Order Flow (FINRA, ~3w lag)
10.4%retail-6.7pp
17.3%dark-2.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Aura Biosciences, Inc.: The Dilution Treadmill for Clinical Survival
Overall Risk
7/10
Fraud
2/10
Dilution
9/10
Insolvency
6/10
Earnings Overstated
1/10
Hidden Liabilities
5/10
Legal
3/10
Audit Warnings
4/10
Hidden Upside
6/10
Contextually Acceptable
8/10